News | August 16, 2025
Cohance Lifesciences reports 13% revenue growth in Q1 FY26
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Rivaroxaban is used to treat venous thromboembolism
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
The agreement complements other PPAs for Sandoz production sites globally
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
Subscribe To Our Newsletter & Stay Updated
